Comparative effectiveness research using matching-adjusted indirect comparison: An application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue SUPPL.2, 2012, Pages 130-137

  Signorovitch, James ^a   Erder, M Haim ^b   Xie, Jipan ^a   Sikirica, Vanja ^b   Lu, Mei ^a   Hodgkins, Paul S ^b   Wu, Eric Q ^a  

^a ANALYSIS GROUP   (United States)

^b SHIRE   (United States)

Author keywords

Attention deficit hyperactivity disorder (ADHD); Comparative effectiveness; Matching adjusted indirect comparison; Nonstimulants; Oppositional defiant disorder (ODD)

Indexed keywords

ATOMOXETINE; GUANFACINE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILDHOOD DISEASE; COMPARATIVE EFFECTIVENESS; CONNER PARENT RATING SCALE REVISED SHORT FORM OPPOSITIONAL SUBSCALE; HUMAN; OPPOSITIONAL DEFIANT DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DELAYED-ACTION PREPARATIONS; GUANFACINE; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHARMACOEPIDEMIOLOGY; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860561495     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3246     Document Type: Article

References (38)

1. Report to the President and the Congress on Comparative Effectiveness Research, US Department of Health and Human Services, accessed July 15, 2011.
2. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.
3. Eckert L, Falissard B. Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR. Curr Med Res Opin 2006; 22(11): 2313-2321.
4. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007; 26: 1237-1254.
5. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9(26): 1-134.
6. Sutton A, Ades AE, Cooper N, et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008; 26: 753-767.
7. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313-2324.
8. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices-part 2. Value Health 2011 Jun; 14(4): 429-437.
9. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health 2011 Jun; 14(4): 417-428.
10. Wells GA, Sultan SA, Chen L, et al. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009.
11. NICE Guide to the Methods of Technology Appraisal.
12. Phillips A. 2003 Trial and error: cross-trial comparisons of antiretroviral regimens. AIDS 2003; 17: 619-623.
13. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23(4): 570-578.
14. Deeks JJ, Higgins JPT, Altman DG, editors. Analysing and presenting results. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6; Section 8. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
15. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618-1624.
16. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894-898.
17. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer; a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
18. Moore RA, McQuay HJ. Single-patient data metaanalysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain 1997; 69: 287-294.
19. Turner RM, Omar RZ, Yang M, et al. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 2000; 19: 3417-3432.
20. Neumann PJ, Drummond MF, Jönsson B, et al. Are key principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care 2010; 26: 1: 71-78.
21. Ross SD. Trends in meta-analysis. Drug Inf J 2009; 43: 171-176.
22. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010; 28(10): 935-945
23. National Health Interview Survey. Hyattsville, MD.: National Center for Health Statistics; 2009. Available at accessed on 06/08/11
24. National Collaborating Centre for Mental Health. Attention Deficit Hyperactivity Disorder: Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72, March 2009.
25. Pliszka SR, Crismon ML, Hughes CW, et al. Texas consensus conference panel on pharmacotherapy of childhood attention deficit hyperactivity disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 Jun; 45(6): 642-657.
26. American Academy of Pediatrics. Subcommittee on attention-deficit/hyperactivity disorder and committee on quality improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001 Oct; 108(4): 1033-1044.
27. Findling RL. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Ther 2008 May; 30(5): 942-957.
28. Wilens TE. Update on attention deficit hyperactivity disorder, I. Curr Affect Illness. 1996; 15: 5-12.
29. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010 Sep 1; 24(9): 755-768.
30. Kaplan S, Heiligenstein J, West S, et al. Efficacy and safety of Atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 2004 Oct; 8(2): 45-52.
31. Dell'Agnello G, Maschietto D, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol 2009 Nov; 19(11): 822-834.
32. Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005 Mar; 44(3): 240-248.
33. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine ADHD/ODD study group. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008 Feb; 121(2): e314-e320.
34. Hazell P, Becker K, Nikkanen EA, et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Atten Defic Hyperact Disord. 2009 Dec;1(2):201-210.
35. Hazell P, Zhang S, Wolanczyk T, et al. Comorbid oppositional defiant disorder and the risk of relapse during 9months of atomoxetine treatment for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2006 Mar; 15(2): 105-110.
36. Conners CK, Sitarenios G, Parker JD, et al. The Revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998; 26(4): 257-268.
37. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV:Checklists, Norms, and Clinical Interpretations. New York, NY: The Guilford Press, 1998.
38. Casella G, Berger RL. 2002. Statistical Inference. Duxbury, Thomson Learning, Pacific Grove, CA, 2002.